Bioxyne Posts 215% Revenue Growth, Projects $65–75m in FY26
Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.
- FY25 revenue surged 215% to $30.4 million
- Positive EBITDA of $5.4 million and net profit of $4.9 million
- Secured €3.2 million German supply contract and A$7 million NectarTek deal
- Expanded Australian production capacity targeting 25% market share in FY26
- FY26 guidance – $65–75 million revenue and $11.5–13.5 million EBITDA
Record Growth in FY25
Bioxyne Limited has reported a landmark financial year for FY25, posting a record $30.4 million in revenue, a striking 215% increase over the prior year. This surge was primarily driven by the Australian medical cannabis market, where Bioxyne expanded its footprint through new contracts and increased volumes from existing clients. The company also achieved a maiden positive EBITDA of $5.4 million and net profit after tax of $4.9 million, signaling a strong turnaround from previous losses.
Strategic Contract Wins and Capacity Expansion
Key to Bioxyne’s growth was securing multiple significant contracts, including a €3.2 million supply agreement with a German client and a A$7 million exclusive deal with NectarTek Australia. These deals underpin the company’s international expansion ambitions. Concurrently, Bioxyne doubled its Good Manufacturing Practice (GMP) flower packing capacity to 30 tonnes, positioning itself to capture an estimated 25% share of the Australian medicinal cannabis flower market in FY26.
International Market Entry and Regulatory Progress
Bioxyne’s strategic entry into European and UK markets is gaining momentum. The company achieved GMP certification allowing exports to Europe, Canada, Singapore, and the UK. Construction of a manufacturing facility in Czechia is underway, targeting completion in calendar year 2026 to serve the growing EU market. In the UK, Bioxyne is establishing a GMP-certified manufacturing and distribution facility, supported by government incentives, to tap into a rapidly expanding patient base.
Robust FY26 Outlook
Looking ahead, Bioxyne has upgraded its FY26 guidance to $65–75 million in revenue and $11.5–13.5 million in underlying EBITDA. Growth drivers include increased demand from Australian clients launching new product lines, onboarding new customers, and leveraging higher pricing dynamics in Germany and the UK. The company plans to optimize operational leverage with a stable cost base and limited incremental investment required to support both domestic and international expansion.
Financial Strength and Market Position
Bioxyne ended FY25 with $7.7 million cash on hand, supporting multiple growth initiatives. The company’s balance sheet reflects significant investment in production capabilities and inventory to meet expanding demand. With a market capitalization of approximately $126 million and a share price steady near its 52-week high, Bioxyne is well positioned to capitalize on the accelerating global medical cannabis market.
Bottom Line?
Bioxyne’s FY25 momentum sets the stage for aggressive growth in FY26, but execution in new international markets will be critical to sustaining its upward trajectory.
Questions in the middle?
- How quickly will Bioxyne’s Czechia facility ramp up production to meet EU demand?
- What impact will competitive pressures have on Bioxyne’s targeted 25% Australian market share?
- How will regulatory changes in Europe and the UK affect Bioxyne’s expansion plans?
